about
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesThalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigensImpact of pomalidomide therapy in multiple myeloma: a recent survey.Novel approaches to Behçet's disease.Immunotherapeutic and antitumour potential of thalidomide analogues.Thalidomide use in pediatric patients.Identification of new therapeutic targets for prevention of CNS inflammation.Thalidomide: a new anticancer drug?Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individualsDifferential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 miceGenerating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide.Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathwayPhase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c miceShared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach.Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.Thalidomide-induced amenorrhoea: two cases.Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide- treated mice.(+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF-alpha in LPS-stimulated macrophages.Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease.Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders.Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
P2860
Q24806367-BA700E2E-FD37-48CD-B9FA-B26D0B851E8BQ28362572-ADC79A30-E51A-481A-9D3E-9C167443539DQ33416346-E7560D66-20F4-451F-856D-F634BCDB63E9Q34075044-B1458B9C-5621-4923-BF19-278E9A080398Q34451909-A6CDADC7-A925-4A7C-A04F-1D192A500572Q34564331-1533CDEC-45B1-440E-830C-D3A4D3598130Q34837632-CEF986B5-3F67-4863-8B99-8D69D291CDBEQ35164773-1F5D108F-290E-4871-A043-A38801A5C192Q35663886-E02F7488-4A2F-432C-9643-B20E673A83FAQ35757592-A01971E5-58C9-4D55-A48F-0D4D37D6E02BQ36168669-F9F7B1CA-7F45-49C7-A414-66C977208704Q36309724-EDC40A24-2860-448A-A993-975B042F8EF7Q36696902-6AD0F6E0-6A5A-4808-8ED5-D513760B4223Q36868265-0AEF28DD-9FE9-4762-B56E-6EEE8BB9895EQ37117375-5B5348C3-5AA4-46E1-AEF3-D76C4F7842A7Q38976707-CA5E2E04-6B34-4A28-AA8A-06357B8459ACQ39417367-393FE7E9-9FEB-47CA-BA0A-DE0CB00DA024Q43650523-AA6380B2-AB92-4E95-B274-F9159C878301Q44041377-552F308C-C6FF-4A9E-88BE-4A11D180B44AQ44150673-84CB6227-F021-4532-8723-CF9DBF5FCA48Q44830579-08D09A54-41AA-4071-9C09-B285A0ABB6B3Q46533341-9D4C63E9-8152-48CA-8D25-255319DF1512Q46921942-2FE68EAB-5295-416C-B576-56B15A663FEDQ47423838-AC2D32D1-CC6C-4C7F-872E-381DBC313149Q47568643-A9274AA0-775C-4777-A897-07FED451270B
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Thalidomide as an emerging immunotherapeutic agent.
@ast
Thalidomide as an emerging immunotherapeutic agent.
@en
type
label
Thalidomide as an emerging immunotherapeutic agent.
@ast
Thalidomide as an emerging immunotherapeutic agent.
@en
prefLabel
Thalidomide as an emerging immunotherapeutic agent.
@ast
Thalidomide as an emerging immunotherapeutic agent.
@en
P2093
P1433
P1476
Thalidomide as an emerging immunotherapeutic agent.
@en
P2093
Dalgleish AG
Marriott JB
P304
P356
10.1016/S0167-5699(99)01531-5
P577
1999-12-01T00:00:00Z